Ali H, et al. - Via analyzing data from the British Renal Transplant Registry, researchers sought to determine how interleukin-2 (IL-2) receptor blocker induction therapy affects allograft and patients’ outcomes in standard risk recipients in the tacrolimus era. They assessed, in all, 3,597 renal transplant patients in the study. Among these, 2,858 received IL-2 receptor blocker induction therapy and 739 did not receive the induction therapy. Outcomes revealed no effect of the IL2 receptor blocker induction regimen on estimated glomerular filtration rate at 1 year or renal and graft outcomes at 5 years in the standard risk renal transplant population.